BRSR for the Financial year ended March 31, 2026

August 27, 2026 The Department of Corporate Services- Listing The Department of Corporate Services- Listing BSE Ltd, National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street Bandra Kurla Complex, Mumbai-400 001 Bandra (E) Mumbai – 400 051 Scrip Code: 507789 Symbol: JAGSNPHARM Subject: Business Responsibility and Sustainability Report for the financial year 2025-26 Dear Sir/ Madam, Pursuant to Regulation 34(2)(f) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015, please find enclosed the Business Responsibility and Sustainability Report (“BRSR”) for the financial year 2025- 26 which forms part of the Annual Report for the financial year 2025-26. We request you to take the above on record. Thanking you, For Jagsonpal Pharmaceuticals Limited Pratham Rawal Company Secretary & Compliance Officer Encl.: A/a Corporate Overview | Statutory Reports | Financial Statements Business Responsibility and Sustainability Report Section A: General Disclosures I. Details of the listed entity 1. Corporate Identity Number (CIN) L74899DL1978PLC009181 2. Name of company Jagsonpal Pharmaceuticals Limited 3. Year of incorporation 1978 4. Registered office address Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 5. Corporate office address Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar, Sector 18, Gurugram -122 015, Haryana (India) 6. E-mail cs@jagsonpal.com 7. Telephone +91 124 4406710 8. Website www.jagsonpal.com 9. Financial year for which reporting is being done April 1, 2025 – March 31, 2026 10. Name of the stock exchange(s) where shares are BSE Limited and National Stock Exchange of India Limited listed 11. Paid-up capital (In ₹) ₹ 13,39,24,500/- 12. Name and contact details (telephone, email Name: Mr. Pratham Rawal, Designation: Company Secretary, address) of the person who may be contacted in Telephone no.: +91 124 4406710 case of any queries on the BRSR report Email ID: cs@jagsonpal.com 13. Reporting boundary Standalone basis 14. Name of assurance provider NA 15. Type of assurance obtained NA II. Products/services 16. Details of business activities (accounting for 90% of the turnover): The company is engaged in the business of marketing and distribution of pharmaceutical formulations. 17. Products/Services sold by the entity (accounting for 90% of the entity’s Turnover): Product/Service NIC Code % of total turnover contributed 1. Pharmaceutical formulations 21002 99.42% III. Operations 18. Number of locations where plants and/or operations/offices of the entity are situated: • Registered Office in New Delhi • Corporate Office in Gurugram, Haryana • Branch Office in Mumbai, Maharashtra • Warehouse in Ghaziabad, Uttar Pradesh 19. Markets served by the entity (A) No. of locations Locations Number National (No. of States) 28 International (No. of Countries) 2 Jagsonpal Pharmaceuticals Limited | Annual Report 2025-26 (B) What is the contribution of exports as a percentage of the total turnover of the entity? Exports – The Company exports products to Bangladesh & Malaysia. Exports contribute 0.09% of the total turnover of the company. (C) A brief on types of customers? Customers – The customers are important stakeholders in our business. The primary channels of distribution is through Stockist and Institutional Buyers. IV. Employees 20. Details as at the end of Financial Year a. Employees and workers (including differently abled): Sr. Total Male Female Particulars No. (A) No. (B) % (B / A) No. (C) % (C / A) EMPLOYEES 1 Permanent (D) 1297 1266 98% 31 2% 2 Other than Permanent (E) 8 8 100% 0 - 3 Total employees (D + E) 1305 1274 98% 31 2% WORKERS 4 Permanent (F) - - - - - 5 Other than Permanent (G) - - - - - 6 Total employees (F + G) - - - - - b. Differently abled Employees and workers: S. Total Male Female Particulars No. (A) No. (B) % (B / A) No. (C) % (C / A) Employees Permanent (D) 0 0 0% 0 0% 2. Other than Permanent (E) 0 0 0% 0 0% 3. Total differently abled employees (D + E) 0 0 0% 0 0% Workers 4. Permanent (F) 0 0 0% 0 0% 5. Other than Permanent (G) 0 0 0% 0 0% 6. Total differently abled workers (F + G) 0 0 0% 0 0% 21. Participation/Inclusion/Representation of women (As at 31 March, 2026) Total No. and percentage of Females (A) No. (B) % (B / A) Board of Directors (including MD) 6 2 33% Key Managerial Personnel (CFO and CS) 2 0 0% 22. Turnover Rate for Permanent Employees and Workers: FY 2025-26 FY 2023-24 (Turnover rate in the FY 2024-25 (Turnover rate in (Turnover rate in current FY) year Prior to the previous FY) previous FY) Resignations Resignations Resignations Male Female Total Male Female Total Male Female Total Permanent 57% 1% 58% 51% 1% 52% 58% 1% 59% Employees Permanent - - - - - - - - - Workers V. Holding, Subsidiary and Associate Companies (including joint ventures) Corporate Overview | Statutory Reports | Financial Statements 23. (A) Names of holding/subsidiary/associate companies/joint ventures Does the entity indicated Name of the holding/subsidiary/ Indicate whether holding/ % of shares at column A, participate in associate companies/ subsidiary/associate/ held by listed the Business Responsibility joint ventures (A) joint venture entity initiatives of the listed entity? (Yes/No) As on March 31, 2026, Company does not have any Subsidiary, Associate or Joint Venture Company. However as on date of this report Company has Subsidiary named Aequitas Healthcare Pvt Ltd in which Company holds 85% equity stake. VI. CSR Details 24. i. Whether CSR is applicable as per Section 135 of Companies Act, 2013: Yes ii. Turnover (in Millions) – ` 2872.25 iii. Net worth (in Millions) – ` 2942.09 VII. Transparency and Disclosures Compliances 25. C omplaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct: Stakeholder FY 2025-26 FY 2024-25 Grievance Redressal group from Current Financial Year Previous Financial Year Mechanism in Place whom complaint (Yes/No) is received (If Yes, then Number of Number of Remarks Number of Number of Remarks provide web-link for complaints complaints complaints complaints grievance redress filed pending filed pending policy) during the resolution at during the resolution year close of the year at close of year the year Communities info@jagsonpal.com 0 0 NA 0 0 NA Investors cs@jagsonpal.com 0 0 NA 0 0 NA (other than shareholders) Shareholders cs@jagsonpal.com 5 0 NA 7 1 Pending complaint has been resolved Employees and info@jagsonpal.com 0 0 NA 0 0 NA workers Customers customercare@ 7 0 4 0 NA jagsonpal.com Consumers can raise a concern via post, via email (customercare@ jagsonpal.com) and reach out to us directly via telephone (+91-124 4406710). Also the consumer can reach out to the Company through official communication channel available on our website www.jagsonpal.com Value Chain - - - - - - - Partners Other (please - 0 0 NA 0 0 NA specify) Jagsonpal Pharmaceuticals Limited | Annual Report 2025-26 26. Overview of the entity’s material responsible business conduct issues The material issues are risks to the Company but at the same time, if acted upon proactively, could provide significant opportunities for the company over its competitors. Some material issues identified are as follows – Financial implications Indicate of the risk or ESG whether opportunity Material issues Management approach Dimension risk or (Indicate opportunity positive or negative implications) Business Prevention of Risk The company is committed to preventing Negative Ethics bribery and bribery and corruption. It fosters a transparent corruption work environment where management and key personnel are readily accessible. To support this, policies such as the Whistleblower Policy have been implemented. Both External and Internal Stakeholders are encouraged to report any malpractices observed within the Company without any fear of retaliation. Data protection Risk The Company has a robu [Showing first 8,000 characters — download PDF for full document]